Recently, many countries reported that Chinese expatriates who had been vaccinated with domestic vaccines were infected with the Chinese Communist Party virus (Wuhan Pneumonia) before going abroad, showing that the domestic vaccines they had been vaccinated with seemed to be ineffective. China will buy no less than 100 million doses of German vaccine by 2021, a statement from Shanghai Fosun Pharmaceutical Group said yesterday.
In a statement sent to the Hong Kong stock Exchange yesterday, Shanghai Fosun Pharma said Germany’s BioNTech would supply China with no less than 100m doses of vaccine by 2021, Reuters and other foreign media reported. Fosun will pay 250 million euros for the first 50 million doses.
Shanghai Fosun Pharmaceutical Owns the rights to the vaccine in The Chinese market, and the two sides signed a cooperation agreement in March, local media Jiemian News reported.
BioNTech’s mRNA (MESSENGER RNA) vaccine, developed in partnership with Pfizer (PFE) of the US, is the world’s first Chinese viral vaccine to publish phase III clinical data. Analysis of the data shows that the vaccine is 90 per cent protective and has received emergency approvals in the US and UK.
China’s communist Party has been trying to gain an international say in vaccine development since the global outbreak of the virus. A number of Chinese drug companies have announced phase III trials, but none has yet received final approval. More than a million people in China have been vaccinated against the vaccine, which is still in its experimental stage, and officials require migrant workers to be vaccinated with domestic vaccines before leaving the country.
But in recent days, at least 17 Chinese nationals have been infected in Angola, 16 of them employees of a State-owned Chinese company in Lunda Norte province. And these infected Chinese people, before going abroad, have been in accordance with the official arrangement, unified vaccination sinopharm group developed vaccines.
Ms. You, a Chinese in Angola, confirmed the news to RADIO Free Asia.
Meanwhile, news leaked online that about 300 of the more than 400 employees in a project department of The Tianjin Electric Power Construction Company in Pancevo, Serbia, had been confirmed. They include a large number of employees from China, who have also been vaccinated with domestic vaccines before going abroad.
Tianjin Power Construction has remained silent. Calls to the company by Free Asia Point have been rejected, and its official website and numerous web pages on the company’s Serbian projects have been removed.
Earlier this month, China News Service, the official media of the Communist Party of China, quoted a statement by the Embassy of the Communist Party of China in Uganda, as saying that 47 Chinese citizens working in an Indian company in Uganda have tested positive for the virus.
According to official regulations, these people should also have been vaccinated against domestic vaccines.
Sinopac’s data on vaccine development have not been disclosed. Of the several vaccine companies currently in phase III trials in China, only data from phase I and phase II trials of sinovac’s inactivated vaccines were published last month in the Lancet, a leading British medical journal. It said the vaccine induced a rapid antibody response within four weeks of the injection.
But the data showed that vaccinators produced lower levels of antibodies than those who had novel Coronavirus. In the Pfizer and Modena trials, the levels of antibodies in those vaccinated were about the same as those in people infected with the virus.
Li Dunhou, a former professor at the Harvard School of Public health in the United States, once told RADIO Free Asia that “the presence of an immune response does not mean that there is a protective effect for people infected with the virus.”
Questions have been raised about the safety and efficacy of Vaccines made in China. According to Deutsche Welle, several Chinese vaccine manufacturers have caused a number of medical disputes abroad. Sinopharm is involved in medical lawsuits in 10 countries around the world, including the United Arab Emirates, Egypt, Jordan, Peru and Argentina, involving up to 60,000 volunteers.
Sinovac has lawsuits in Brazil, Turkey and Indonesia.
Recent Comments